The Scottish Medicines Consortium (SMC) published advice on eight medicines following its meeting on 12 October 2026.3 Six medicines were accepted for use on the NHS in Scotland; two were not recommended.
Accepted for use
- Mirvetuximab soravtansine (Elahere, AbbVie) – platinum-resistant, folate receptor alpha (FRĪ±)-positive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults who have received one to three prior lines of systemic therapy.
- Vutrisiran (Amvuttra, Alnylam) – transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) in adults.
- Obinutuzumab (Gazyvaro, Roche) – active lupus nephritis in adults in combination with mycophenolate mofetil and corticosteroids.
- Standardised white birch pollen allergen extract (Itulazax, ALK) – moderate to severe allergic rhinoconjunctivitis caused by birch pollen in adults who have had an inadequate response to antihistamines and nasal corticosteroids.
- Atogepant (Aquipta, AbbVie) – preventive treatment of migraine in adults who have at least four migraine days per month.
- Deuruxolitinib (Leqselvi, Sun Pharma) – severe alopecia areata in adults.
References – Scotland
3. October 2026 decisions news release. Scottish Medicines Consortium. October 2026. https://scottishmedicines.org.uk/about-us/latest-update/october-2026-decisions-news-release/
